XML 98 R79.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Sale of Pegzilarginase to Immedica (Details) - USD ($)
$ in Thousands
12 Months Ended
Jul. 27, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Proceeds from sale of intangible assets   $ 15,000 $ 0 $ 0
Gain on sale of in-process research and development asset   $ 16,449 $ 0 $ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights To Pegzilarginase        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Proceeds from sale of intangible assets $ 15,000      
Contingent consideration 100,000      
Carrying value of assets 0      
Gain on sale of in-process research and development asset 16,400      
Contingent reimbursement of pre-paid manufacturing costs 1,800      
Derecognition of nonfinancial assets and liabilities $ 400